HMH Invests in Adaptive Phage Therapeutics   

HMH Invests in Adaptive Phage Therapeutics

December 04, 2019

Hackensack Meridian Health has invested in the clinical-stage biotechnology company Adaptive Phage Therapeutics (APT), as part of the health network’s successful innovation program, the Bear’s Den.

APT is taking aim at the toughest multi-drug resistant “superbugs” using precision-targeted, genomically-screened, and highly purified viruses known as bacteriophages, or “phages.”

Read More

We use cookies to improve your site experience. By using this site,
you agree to our Terms & Conditions. Also, please read our Privacy Policy. Accept All CookiesLearn More